Reading ZNTL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ZNTL free→Reading ZNTL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ZNTL free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been fairly steady. Risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 15% above where it trades (it looks cheap on this basis); the read is fair, but weakening. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.78. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.78 ZNTL trades at 10× p/s, in line with its 9× p/s peer median. Our $4.42 fair value reflects that, medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 15% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.01x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
8 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.46 → $-0.46 (+0.0% / 30d). 0 raised, 0 cut, 7 covering analysts.
0 upgrades, 0 downgrades / 30d. 44% of analysts rate Buy.
1 PT revisions / 30d. Avg target 141.5% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$251.
How much price usually moves either way.
On a bad day, this stock has moved -$882.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,675.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If the healthcare sector's revenue growth speeds up, it could help Zentalis. It may signal a better market for their drugs.
Confirms:Healthcare sector revenue growth returns to above 10% year over year.
Disproves:Healthcare sector revenue growth remains below 10% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ZNTL yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director. Ms. Campbell's initial term is scheduled to expire at the Company's 2027 Annual Meeting of Stockholders, subject to the election and qual…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ZNTL Zentalis Pharmaceuticals Inc | Typical Show detailsSector percentile: 32 of 100 | fair | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 77 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Zentalis aims to complete enrollment in all cohorts of DENALI Part 2 and provide a topline readout by the end of 2026.
Stated in 2 of last 2 quarters. The company has not provided specific financial metrics related to this priority. The recurring focus on completing DENALI Part 2 enrollment by year-end 2026 shows a consistent strategic direction, but substantive delivery remains to be seen.
“DENALI Part 2 topline readout expected by year end 2026”
“DENALI Part 2 topline readout expected by year end 2026”
Zentalis is progressing the ASPENOVA Phase 3 trial to support full approval of azenosertib in Cyclin E1-positive PROC.
Newly stated in 2026-Q1. The company has initiated the ASPENOVA Phase 3 trial, marking progress in its clinical development pipeline. However, financials do not yet reflect revenue from this initiative, as revenue remains at $0.0 in recent quarters.
“The first patient has been dosed in the Phase 3 ASPENOVA clinical trial evaluating azenosertib.”
Zentalis has selected the optimal monotherapy dose of azenosertib for the DENALI Phase 2 trial.
Newly stated in 2026-Q1. The company has optimized the dosing schedule for azenosertib in the DENALI trial, which is a step forward in clinical development. Financials do not yet show revenue impact, as revenue remains at $0.0 in recent quarters.
“The Company announced the selection of 400mg once daily on a 5-days-on, 2-days-off schedule as the optimal monotherapy dose.”
Results of Operations and Financial Condition. On May 12, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026, and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and is incorporated herein by reference.
Other Events. On May 21, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society of Clinical Oncology ("ASCO") Annual Meeting, being held May 29 – June 2, 2026, in Chicago, Illinois. MUIR is a multi-part, open-label Phase 1b clinical trial evaluating azenosertib in combination with chemotherapy in patients with ovarian cancer. Part 1 evaluated azenosertib in combination with four chemotherap…
Other Events. On May 5, 2026, the Company announced that the first patient has been dosed in the Phase 3 ASPENOVA clinical trial evaluating azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer ("PROC"). ASPENOVA is a Phase 3 randomized, confirmatory clinical trial designed to support full approval of azenosertib in patients with Cyclin E1-positive PROC. The trial is expected to enroll approximately 420 patients and compare azenosertib monotherapy at 400mg QD 5:2 (…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on March 26, 2026 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: March 26, 2026 By: /s/ Julie Eastland Julie Eastland President and Ch…